The Department of Homeland Security, specifically the U.S. Coast Guard (USCG), is issuing a Request for Information (RFI) to explore the market for medical point-of-care molecular disease analyzers, with the intent to replace its aging Cepheid GeneXpert systems. The USCG aims to procure approximately 55 new devices that can test for multiple diseases, including SARS-CoV-2, Influenza A and B, and various bacterial infections, emphasizing the need for FDA approval, high specificity and sensitivity, rapid turnaround times within 60 minutes, and compatibility with electronic health records. This initiative is crucial for enhancing the USCG's medical capabilities and ensuring timely disease detection among personnel. Interested vendors are encouraged to submit their responses by March 25, 2025, and can direct inquiries to Jamison Harned at jamison.w.harned@uscg.mil or by phone at 571-613-5151.